Efficacy of ezetimibe for reducing serum low‐density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non‐alcoholic fatty liver disease
Hepatology Research2013Vol. 44(7), pp. 812–817
Citations Over Time
Noriko Oza, Kazuhiro Takahashi, Yuichiro Eguchi, Yoichiro Kitajima, Takuya Kuwashiro, Eriko Ishibashi, Shunya Nakashita, Shinji Iwane, Yasunori Kawaguchi, Toshihiko Mizuta, Iwata Ozaki, Naofumi Ono, Takahisa Eguchi, Kazuma Fujimoto, Keizo Anzai
Abstract
Ezetimibe is effective for treating residual dyslipidemia after lifestyle intervention in patients with NAFLD.
Related Papers
- → Review article: is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions?(2012)215 cited
- → Low‐density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real‐world evidence(2020)11 cited
- → Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea Adverse Events Reporting System Database, 2005 – 2016(2019)2 cited
- → Statin plus Extended Release Niacin is More Effective than Statin plus Ezetimibe in Reducing CIMT(2009)
- → Attainment of accaha recommended LDL C lowering with statin and ezetimibe statin therapies(2016)